Ustekinumab (Stelara — Janssen Inc.) indication: psoriatic arthritis

Record ID 32015000166
Authors' recommendations: The Canadian Drug Expert Committee (CDEC) recommends that ustekinumab not be listed at the submitted price for the treatment of psoriatic arthritis.
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Psoriatic
  • Immunosuppressive Agents
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha
  • Methotrexate
  • Antirheumatic Agents
  • Drug Approval
  • Psoriasis
  • Canada
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.